REGN:NGS-Regeneron Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 1053.14

Change

0.00 (0.00)%

Market Cap

USD 42.08B

Volume

1.27M

Analyst Target

USD 674.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.49 (-0.31%)

USD 122.24B
MRNA Moderna Inc

-1.27 (-1.04%)

USD 51.07B
ALNY Alnylam Pharmaceuticals Inc

+1.83 (+0.75%)

USD 28.20B
ARGX argenx NV ADR

-0.94 (-0.21%)

USD 26.78B
BNTX BioNTech SE

-2.14 (-2.59%)

USD 20.40B
BGNE BeiGene Ltd

-0.86 (-0.59%)

USD 17.50B
GMAB Genmab AS

-0.09 (-0.35%)

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

-1.75 (-2.05%)

USD 15.98B
RPRX Royalty Pharma Plc

+0.09 (+0.34%)

USD 15.90B
UTHR United Therapeutics Corporatio..

-2.02 (-0.63%)

USD 13.71B

ETFs Containing REGN

2B70:XETRA iShares Nasdaq US Biotech.. 8.44 % 0.00 %

-0.04 (-0.69%)

USD 0.52B
CURE:XETRA VanEck Genomics and Healt.. 8.34 % 0.00 %

-0.21 (-0.69%)

USD 7.06M
BTEC:SW iShares Nasdaq US Biotech.. 8.30 % 0.00 %

-0.14 (-0.69%)

USD 0.52B
CURG:LSE VanEck Genomics and Healt.. 8.28 % 0.00 %

-0.11 (-0.69%)

USD 7.06M
HHL-B:CA Harvest Healthcare Leader.. 5.29 % 0.00 %

-0.06 (-0.69%)

N/A
SPQH:XETRA Global X S&P 500® Quarte.. 4.95 % 0.00 %

+0.01 (+-0.69%)

USD 0.05B
EMEH:XETRA BNP Paribas Easy Energy &.. 4.80 % 0.00 %

+0.06 (+-0.69%)

USD 0.11B
GSDE:XETRA BNP Paribas Easy Energy &.. 4.80 % 0.00 %

+0.05 (+-0.69%)

USD 0.47B
EMEH:SW BNP Paribas Easy Energy &.. 4.80 % 0.00 %

N/A

USD 0.04B
GSCE:SW BNP Paribas Easy Energy &.. 4.80 % 0.00 %

N/A

USD 0.27B
GSCU:SW BNP Paribas Easy Energy &.. 4.80 % 0.00 %

+0.16 (+-0.69%)

USD 0.17B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.70 % 0.00 %

-0.16 (-0.69%)

USD 3.56M
ZWHC:CA BMO Covered Call Health C.. 4.69 % 0.00 %

-0.29 (-0.69%)

CAD 0.01B
UBIO 4.54 % 0.95 %

N/A

N/A
EGUSAS:SW UBS (Irl) Fund Solutions .. 4.35 % 0.00 %

+0.06 (+-0.69%)

USD 0.09B
XDNA:CA iShares Genomics Immunolo.. 4.28 % 0.00 %

-0.30 (-0.69%)

CAD 4.90M
MEDX Horizon Kinetics Medical .. 4.15 % 0.00 %

-0.01 (-0.69%)

USD 0.02B
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.15 % 0.00 %

-0.22 (-0.69%)

USD 0.15B
FDG American Century ETF Trus.. 4.00 % 0.00 %

+0.07 (+-0.69%)

USD 0.23B
HEAL:CA 3.97 % 0.00 %

N/A

N/A
SYNB Putnam Biorevolution ETF 3.83 % 0.00 %

-0.12 (-0.69%)

USD 5.43M
FBT:LSE First Trust Global Funds .. 3.74 % 0.00 %

-3.10 (-0.69%)

USD 5.59M
FBTU:LSE First Trust Global Funds .. 3.74 % 0.00 %

+0.01 (+-0.69%)

USD 5.59M
ENTR ERShares Entrepreneurs ET.. 3.69 % 0.49 %

+0.12 (+-0.69%)

USD 0.09B
AGNG Global X Aging Population.. 3.34 % 0.00 %

-0.08 (-0.69%)

USD 0.06B
KONG Formidable Fortress ETF 3.11 % 0.00 %

-0.03 (-0.69%)

USD 0.02B
PVAL Putnam Focused Large Cap .. 2.92 % 0.29 %

-0.09 (-0.69%)

USD 0.64B
CGGR Capital Group Growth ETF 2.38 % 0.00 %

+0.05 (+-0.69%)

USD 6.09B
CAPS:LSE First Trust Capital Stren.. 2.30 % 0.00 %

-3.75 (-0.69%)

USD 0.02B
FTCS:LSE First Trust Capital Stren.. 2.26 % 0.00 %

-0.06 (-0.69%)

USD 0.02B
XLVE:CA Mulvihill U.S. Health Car.. 1.84 % 0.00 %

-0.08 (-0.69%)

CAD 7.02M
SM8T:XETRA Amundi Index Solutions - .. 0.53 % 0.00 %

-0.60 (-0.69%)

USD 0.04B
SMRU:PA Amundi Index Solutions - .. 0.53 % 0.00 %

+0.80 (+-0.69%)

USD 3.30M
ACWV 0.00 % 0.20 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

-0.25 (-0.69%)

USD 0.43B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+0.10 (+-0.69%)

USD 0.09B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.04 (-0.69%)

USD 3.35M
FPX First Trust US Equity Opp.. 0.00 % 0.59 %

+0.72 (+-0.69%)

USD 0.70B
FTCS First Trust Capital Stren.. 0.00 % 0.60 %

-0.51 (-0.69%)

USD 8.59B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-0.01 (-0.69%)

USD 7.43B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

-0.15 (-0.69%)

USD 0.12B
MUS:CA Mackenzie Maximum Diversi.. 0.00 % 0.58 %

+0.03 (+-0.69%)

CAD 0.10B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.12 (-0.69%)

USD 0.25B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

-0.10 (-0.69%)

USD 0.27B
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

+0.34 (+-0.69%)

USD 0.14B
PXLG 0.00 % 0.39 %

N/A

N/A
TPLC Timothy Plan US Large/Mid.. 0.00 % 0.00 %

+0.01 (+-0.69%)

USD 0.22B
IDNA iShares Genomics Immunolo.. 0.00 % 0.00 %

-0.03 (-0.69%)

USD 0.14B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

-0.07 (-0.69%)

N/A
HERS-B:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.02 (-0.69%)

USD 0.51B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.02 (-0.69%)

USD 0.50B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.04 (-0.69%)

USD 8.18M
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.03 (-0.69%)

USD 0.04B
XMW:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

+0.01 (+-0.69%)

CAD 0.17B
XMY:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

N/A

CAD 0.01B
ZBIO 0.00 % 0.95 %

N/A

N/A
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

-0.10 (-0.69%)

CAD 0.33B
HERS:CA 0.00 % 0.62 %

N/A

N/A
FPX:LSE First Trust Global Funds .. 0.00 % 0.00 %

-2.50 (-0.69%)

USD 6.48M
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

+0.38 (+-0.69%)

USD 3.31M
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
EMEH:PA BNP Paribas Easy Energy &.. 0.00 % 0.00 %

+0.06 (+-0.69%)

USD 0.04B
FPXU:PA First Trust US Equity Opp.. 0.00 % 0.00 %

+0.09 (+-0.69%)

USD 6.43M
GSCU:PA BNP Paribas Easy Energy &.. 0.00 % 0.00 %

+0.06 (+-0.69%)

USD 0.15B
SMRT:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.03B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
EMEH:F BNP Paribas Easy Energy &.. 0.00 % 0.00 %

N/A

N/A
GSDE:F BNP Paribas Easy Energy &.. 0.00 % 0.00 %

N/A

USD 0.27B
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

+0.50 (+-0.69%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
DWEQ 0.00 % 0.00 %

N/A

N/A
LYFE 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

-0.02 (-0.69%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.79% 76% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.79% 76% C+ 83% B
Trailing 12 Months  
Capital Gain 35.06% 81% B- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.06% 81% B- 85% B
Trailing 5 Years  
Capital Gain 236.57% 92% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 236.57% 92% A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 25.54% 77% C+ 82% B
Dividend Return 25.54% 77% C+ 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.80% 88% B+ 64% D
Risk Adjusted Return 88.66% 99% N/A 95% A
Market Capitalization 42.08B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 60.10 19% 30%
Price/Book Ratio 3.82 39% 28%
Price / Cash Flow Ratio 25.05 3% 10%
Price/Free Cash Flow Ratio 19.42 2% 13%
Management Effectiveness  
Return on Equity 15.28% 98% 85%
Return on Invested Capital 14.45% 88% 84%
Return on Assets 7.74% 98% 92%
Debt to Equity Ratio 7.63% 58% 74%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.